Thrombospondin-2 Plays a Protective Role in Multistep Carcinogenesis: a Novel Host Anti-tumor Defense Mechanism

Overview

Journal EMBO J

Specialties Biotechnology
Molecular Biology

Date 2001 Jun 2

PMID 11387198

Citations 44

Authors

T Hawighorst

P Velasco

M Streit

Y K Hong

T R Kyriakides

L F Brown

P Bornstein

M Detmar

Affiliations

Soon will be listed here.

Abstract

The angiogenic switch during tumorigenesis is thought to be induced by a change in the balance of pro- angiogenic and anti-angiogenic factors. To elucidate the biological role of the endogenous angiogenesis inhibitor thrombospondin-2 (TSP-2) during multistep carcinogenesis, we subjected TSP-2-deficient and wild-type mice to a chemical skin carcinogenesis regimen. Surprisingly, TSP-2 expression was strongly upregulated in the mesenchymal stroma of wild-type mice throughout the consecutive stages of tumorigenesis whereas the angiogenesis factor, vascular endothelial growth factor, was induced predominantly in tumor cells. TSP-2 deficiency dramatically enhanced susceptibility to skin carcinogenesis and resulted in accelerated and increased tumor formation. The angiogenic switch occurred in early stages of pre-malignant tumor formation, and tumor angiogenesis was significantly enhanced in TSP-2-deficient mice. While TSP-2 deficiency did not affect tumor differentiation or proliferation, tumor cell apoptosis was significantly reduced. These results reveal upregulation of an endogenous angiogenesis inhibitor during multi step tumorigenesis and identify enhanced stromal TSP-2 expression as a novel host anti-tumor defense mechanism.

Citing Articles

Thrombospondins: Conserved mediators and modulators of metazoan extracellular matrix.

Adams J Int J Exp Pathol. 2024; 105(5):136-169.

PMID: 39267379 PMC: 11574667. DOI: 10.1111/iep.12517.

Thrombospondin-2 promotes the proliferation and migration of glioma cells and contributes to the progression of glioma.

Huang T, Mei Y, Li Y, Chen X, Yu S, Kuang Y Chin Neurosurg J. 2022; 8(1):39.

PMID: 36476392 PMC: 9728004. DOI: 10.1186/s41016-022-00308-x.

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).

Clarke J, Blobe G, Strickler J, Uronis H, Zafar S, Morse M Cancer Chemother Pharmacol. 2019; 84(4):909-917.

PMID: 31444620 PMC: 6769092. DOI: 10.1007/s00280-019-03916-0.

Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer.

Jiang Y, Yu D, Hou G, Jiang J, Zhou Q, Xu X Biosci Rep. 2019; 39(7).

PMID: 31296790 PMC: 6658726. DOI: 10.1042/BSR20190476.

A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.

Berger A, Schwerdel D, Reinacher-Schick A, Uhl W, Algul H, Friess H Theranostics. 2019; 9(5):1280-1287.

PMID: 30867830 PMC: 6401492. DOI: 10.7150/thno.29247.

References

Greenhalgh D, Rothnagel J, Wang X, Quintanilla M, Orengo C, Gagne T . Hyperplasia, hyperkeratosis and benign tumor production in transgenic mice by a targeted v-fos oncogene suggest a role for fos in epidermal differentiation and neoplasia. Oncogene. 1993; 8(8):2145-57. View

Caughey G, Viro N, Calonico L, McDonald D, Lazarus S, Gold W . Chymase and tryptase in dog mastocytoma cells: asynchronous expression as revealed by enzyme cytochemical staining. J Histochem Cytochem. 1988; 36(8):1053-60. DOI: 10.1177/36.8.3134486. View

Zabrenetzky V, Harris C, Steeg P, Roberts D . Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer. 1994; 59(2):191-5. DOI: 10.1002/ijc.2910590209. View

OReilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M . Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79(2):315-28. DOI: 10.1016/0092-8674(94)90200-3. View

Schultz-Cherry S, Chen H, Mosher D, Misenheimer T, Krutzsch H, Roberts D . Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem. 1995; 270(13):7304-10. DOI: 10.1074/jbc.270.13.7304. View

Dejana E, Corada M, Lampugnani M . Endothelial cell-to-cell junctions. FASEB J. 1995; 9(10):910-8. View

Ferrara N . The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat. 1995; 36(2):127-37. DOI: 10.1007/BF00666035. View

Holmgren L, OReilly M, Folkman J . Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995; 1(2):149-53. DOI: 10.1038/nm0295-149. View

Volpert O, Tolsma S, Pellerin S, Feige J, Chen H, Mosher D . Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun. 1995; 217(1):326-32. DOI: 10.1006/bbrc.1995.2780. View

10.

Parangi S, OReilly M, Christofori G, Holmgren L, GROSFELD J, Folkman J . Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A. 1996; 93(5):2002-7. PMC: 39899. DOI: 10.1073/pnas.93.5.2002. View

11.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

12.

Larcher F, Robles A, Duran H, Murillas R, Quintanilla M, Cano A . Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res. 1996; 56(23):5391-6. View

13.

Brown L, Detmar M, Claffey K, Nagy J, Feng D, Dvorak A . Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 1997; 79:233-69. DOI: 10.1007/978-3-0348-9006-9_10. View

14.

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

15.

Hanahan D, Christofori G, Naik P, Arbeit J . Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer. 1996; 32A(14):2386-93. DOI: 10.1016/s0959-8049(96)00401-7. View

16.

Dawson D, Pearce S, Zhong R, Silverstein R, Frazier W, Bouck N . CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997; 138(3):707-17. PMC: 2141641. DOI: 10.1083/jcb.138.3.707. View

17.

Kyriakides T, Zhu Y, Smith L, Bain S, Yang Z, Lin M . Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol. 1998; 140(2):419-30. PMC: 2132586. DOI: 10.1083/jcb.140.2.419. View

18.

Campbell S, Volpert O, Ivanovich M, Bouck N . Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 1998; 58(6):1298-304. View

19.

Volpert O, Lawler J, Bouck N . A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A. 1998; 95(11):6343-8. PMC: 27689. DOI: 10.1073/pnas.95.11.6343. View

20.

Detmar M, Brown L, Schon M, Elicker B, Velasco P, Richard L . Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 1998; 111(1):1-6. DOI: 10.1046/j.1523-1747.1998.00262.x. View